Amneal Pharmaceuticals LLC’s merging with Impax Laboratories, Inc.


Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) have announced that they have agreed to merge in an all-stock transaction.

As a result of the transaction, Amneal Holdings members will own 75% and Impax shareholders will own 25% of the new company’s pro forma shares.

The transaction is expected to close in the first half of 2018, subject to the satisfaction of customary closing conditions, including receipt of regulatory approvals and Impax shareholder approval.

Latham & Watkins LLP represents Amneal in the transaction with a corporate deal team led by partner Charles Ruck (picture) in New York and Orange County and partner Scott Shean in Orange County, with associates Mark Bekheit in Silicon Valley, Daniel Kecman in Washington, D.C., Lilian Balasanian in Los Angeles, Bret Stancil in Silicon Valley, Brad Guest in Washington, D.C., Emily Sairafian in Orange County, Lauren Chase in Silicon Valley, and Cassandra Wang in Silicon Valley. Advice was also provided on finance matters by partners Wesley Holmes and Jesse Sheff, with associates Sonja Pollack and Jake Burne in New York; on securities matters by counsel Ryan deFord, with associate Yi Han Goh in New York; on tax matters by partners Joseph Kronsnoble in Chicago and Nicholas DeNovio in Washington, D.C., with associate Jared Grimley in Houston; on benefits and compensation matters by partner Bradd Williamson in New York and counsel Nineveh Alkhas in Chicago, with associate Jordan Salzman in New York; on antitrust matters by partner Mandy Reeves, with associate Patrick English in Washington, D.C.; on environmental matters by partner Christopher Norton in Orange County and counsel David Langer in New York; on real estate matters by partner Hilary Shalla, with associates Meagan Licata and Kendra Perdue in Orange County; on intellectual property matters by partner Steven Chinowsky and counsel Darryl Steensma in San Diego, with associate Simon Hu in Los Angeles; on intellectual property litigation matters by partner Daniel Brown in New York; and on regulatory matters by partner Ben Haas in Washington, D.C., with associate Amy Speros in Silicon Valley.

Involved fees earner: Charles Ruck – Latham & Watkins; Brad Guest – Latham & Watkins; Emily Sairafian – Latham & Watkins; Lauren Chase – Latham & Watkins; Scott Shean – Latham & Watkins; Mark Bekheit – Latham & Watkins; Daniel Kecman – Latham & Watkins; Lilian Balasanian – Latham & Watkins; Bret Stancil – Latham & Watkins; Cassandra Wang – Latham & Watkins; Jesse Sheff – Latham & Watkins; Wesley Holmes – Latham & Watkins; Sonja Pollack – Latham & Watkins; Jake Burne – Latham & Watkins; Ryan deFord – Latham & Watkins; Yi Han Goh – Latham & Watkins; Joseph Kronsnoble – Latham & Watkins; Nicholas DeNovio – Latham & Watkins; Jared Grimley – Latham & Watkins; Bradd Williamson – Latham & Watkins; Nineveh Alkhas – Latham & Watkins; Jordan Salzman – Latham & Watkins; Amanda Reeves – Latham & Watkins; Patrick English – Latham & Watkins; Christopher Norton – Latham & Watkins; David Langer – Latham & Watkins; Hilary Shalla – Latham & Watkins; Meagan Licata – Latham & Watkins; Kendra Perdue – Latham & Watkins; Steven Chinowsky – Latham & Watkins; Daniel Brown – Latham & Watkins; Darryl Steensma – Latham & Watkins; Simon Hu – Latham & Watkins; Ben Haas – Latham & Watkins; Amy Speros – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Amneal Pharmaceuticals;

Avatar

Author: Ambrogio Visconti